Maxalt Melt (Rizatriptan Benzoate)

Rizatriptan selectively stimulates serotonin 5‑HT1B and 5‑HT1D receptors on cranial blood vessels and trigeminal nerve endings. This causes vasoconstriction of dilated intracranial arteries and blocks the release of inflammatory neuropeptides, interrupting the pain pathway that generates migraine symptoms.

The appropriate dose of Maxalt Melt is determined by a qualified prescriber based on the individual’s medical history, severity of migraine, and response to treatment. Patients should follow the prescribing information and take the medication exactly as directed by their healthcare professional.

The safety of rizatriptan during pregnancy or lactation has not been definitively established. It should only be used if the potential benefit justifies any potential risk to the fetus or infant, and this decision must be made by the prescribing clinician in consultation with the patient.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Compared with other triptans, rizatriptan offers a rapid onset of action and is available as an orally disintegrating tablet, which can be convenient for patients with nausea. Its efficacy and safety profile are similar to other agents in the class, but individual response may vary, making prescriber selection important.

Maxalt Melt should be stored at ambient temperature, below 25 °C. Keep the tablets in the original packaging, protect them from moisture and direct sunlight, and ensure they are out of reach of children.

The tablet is placed on the tongue and allowed to melt without water. It should be taken as soon as migraine symptoms begin, preferably before the headache becomes severe. Patients should not chew or swallow the tablet whole.

Serious risks include chest pain or tightness, which may signal cardiac ischemia, and serotonin syndrome, especially when combined with other serotonergic drugs. Patients should seek immediate medical attention if they experience severe cardiovascular symptoms or signs of serotonin excess such as agitation, hyperthermia, or muscle rigidity.

Maxalt Melt is contraindicated in patients with known hypersensitivity to rizatriptan or other triptans, those with uncontrolled hypertension, recent myocardial infarction, severe coronary artery disease, or a history of stroke. It should also be avoided in individuals taking ergot derivatives or monoamine oxidase inhibitors.